Reviewing ALSFRS-R as the Established Endpoint for ALS Clinical Trials
Time: 1:45 pm
day: Day Two AM
Details:
- Demonstrating and quantifying challenges with the ALSFRS-R endpoint in its current state
- Showcasing evidence from alternative measurements to demonstrate impact on disease progression
- Outlining ongoing strategy to approach regulatory review through leveraging regulatory flexibility
